Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Apple Inc (AAPL) vs Mesoblast Limited (MESO) Price & Performance

Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

Apple Inc vs Mesoblast Limited — how do they compare? Apple Inc trades at $305 (market cap $4.45T), while Mesoblast Limited trades at $16.68 (market cap $2.21B). The key difference: Apple Inc is far larger — about 2013.6× Mesoblast Limited's market cap, and Apple Inc pays a 0.35% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.

AAPLMESO
Market Cap
$4.45T$2.21B
Volume
100,358,844
Sector
TechnologyTechnology
52-Week High
$340.08$20.96
52-Week Low
$224.90$12.88
Enterprise Value
$4.47T$2.21B
Dividend Yield
0.35%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Apple Inc

AAPL trades at $308.26, down 1.62% on the day, with a bearish technical signal and support near $306. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $1.98. Revenue grew to $416.16B in 2025, and net income margin improved to 27.62%. Recent news highlights AI potential through a partnership with Alphabet's Gemini, but store closures and union disputes pose headwinds.

Outlook remains positive with a consensus price target of $337.63, implying 9.5% upside, supported by robust cash flow and a 63.6% buy rating from analysts. Risks include weaker iPhone sales, regulatory fines, and competitive pressures in AI. The stock offers growth potential but requires monitoring of execution risks and macroeconomic trends.

Mesoblast Limited

MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.

Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Apple Inc

Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.

Read more on AAPL

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO